Common Potency/Identity Pitfalls—and Fixes



Common Potency/Identity Pitfalls—and Fixes

Published on 29/11/2025

Common Potency/Identity Pitfalls—and Fixes

Understanding Potency and Identity in Biologics Validation

The validation of potency and identity in biologics, particularly Advanced Therapy Medicinal Products (ATMPs), is pivotal for ensuring the safety and efficacy of pharmaceutical products. Potency refers to the biological activity of a drug in measured doses, while identity confirms that the product is what it claims to be. These attributes are key critical quality attributes (CQAs) that regulators emphasize during the pharmaceutical development lifecycle. To adhere to stringent US FDA, EMA, and MHRA regulations, manufacturers must validate these elements thoroughly to navigate through complexities in their production processes. The understanding of concepts like viral clearance validation, spiking studies, and chain of identity custody (COI) becomes essential for professionals involved in this field.

Step 1: Planning for Potency and Identity Validation

Effective planning is crucial for establishing a robust validation strategy for potency and identity. The first step is to define the intended use of the biologic product and identify the regulatory requirements applicable under guidelines such as FDA Process Validation and ICH Q5A(R2). This ensures alignment with the medical claims made within the product labeling.

Key Considerations:

  • Regulatory Guidance: Familiarize yourself with relevant guidelines from authorities like the FDA and EMA. This includes the recommendations outlined in ICH Q5A, which addresses viral safety evaluation and the need for viral clearance validation.
  • Defining CQAs: Identify the CQAs for potency and identity including their attributes which must be controlled. This can include assay limits, potency range, and identity tests that may include pesiodic evaluations of spiked materials.
  • Risk Assessment: Conduct a risk assessment to prioritize the CQAs based on their impact on product safety, quality, and efficacy.
  • Resource Allocation: Allocate resources for required laboratory conditions, trained personnel, necessary equipment, and material access.

Step 2: Designing Spiking Studies

Spiking studies play a vital role in assessing the effectiveness of a potency assay. These studies involve deliberately adding a known quantity of an active ingredient to a matrix to evaluate the assay’s sensitivity, specificity, and accuracy under different conditions.

Design Considerations:

  • Matrix Selection: Choose appropriate biological matrices that will be representative of the final product. This could include cell culture supernatants or purified proteins.
  • Concentration Levels: Determine spiking levels based on expected potency ranges and user requirements. This should reflect clinically relevant dosages.
  • Statistical Planning: Plan for statistically sound sampling and analysis to ensure the reliability of results. This should include appropriate controls.
  • Data Analysis: Decide upfront on the criteria for acceptance. Identify acceptable limits for variability and trends in the results derived from the spiking studies.

Step 3: Implementation of Closed Systems and Single-Use Systems

As biologics production continues to evolve, the adoption of closed systems and single-use systems has become integral to maintaining aseptic controls and increasing production efficiency. This is particularly significant in line with compliance under the revised Annex 1 regarding manufacturing standards for sterile medicinal products.

Closed Systems:

  • Design and Compatibility: Ensure that the closed systems are compatible with the process to minimize contamination risks. This includes validation of connections and component integrity.
  • Validation Protocols: Develop the validation protocols for system performance, including integrity testing, functional evaluations, and suitable cleaning validation if necessary.

Single-Use Systems:

  • Material Characteristics: Assess the materials for leachables and extractables to ensure quality is maintained through the lifecycle of the single-use systems.
  • Batch Size Variations: Establish validation approaches that factor in variations in batch sizes and process conditions allowing for flexible manufacturing.

Step 4: Establishing the Chain of Identity Custody (COI)

The chain of identity custody (COI) is critical in ensuring that the identity of the biologics product is maintained throughout the manufacturing process. This includes thorough documentation practices along with labels and tracking systems for materials in each stage of production.

Implementation Steps:

  • Documentation Standards: Maintain comprehensive and accurate records of all materials, including source, handling, and transfers. Implement barcode scanning or RFID technology to enable this tracking.
  • Staff Training: Ensure personnel understand the importance of identity control measures, emphasizing training in aseptic techniques and regulatory compliance.
  • Periodic Audits: Conduct regular audits of COI processes to identify areas for improvement, enhancing traceability and compliance.

Step 5: Aligning with Process Performance Qualification (PPQ) and Continued Process Verification (CPV)

To guarantee that a biologics manufacturing process produces a quality product consistently, aligning PPQ with CPV systems is necessary. Tailoring these validations for ATMPs incorporates real-world scenarios so that efficacy, safety, and identity can be confirmed through each production batch.

Essential Components:

  • PPQ Strategy: Establish a strategy that accounts for the variability inherent in the manufacturing of ATMPs. This includes production scaling and mixed material use.
  • Data Collection: Set up systems to capture data related to potency and identity in real-time. This includes key performance indicators to measure trends and validate method robustness.
  • Feedback Loop: Create a feedback loop enabling continuous improvement in both PPQ and CPV methodologies ensuring methods are responsive to process changes.

Step 6: Final Review and Documentation

As with any validation process, a thorough review is paramount before concluding methods related to potency and identity validation. Each aspect must be documented in compliance with the cGMP guidelines set forth by governing regulations.

Document Outline:

  • Validation Master Plan (VMP): Document an overarching validation plan that harmonizes with quality system requirements and specifies the validation activities.
  • Technical Reports: Develop technical reports summarizing findings from spiking studies and closed systems validations. This provides the necessary evidence for regulatory submissions.
  • Change Control Procedures: Implement change control processes for any alterations to the validated methods, ensuring further compliance and review under appropriate regulatory expectations.
  • Final Sign-offs: Secure final approval from relevant stakeholders and regulatory affairs to ensure that all protocols align with organizational and regulatory expectations.

Conclusion

The validation of potency and identity in biologics is a multifaceted undertaking requiring an in-depth understanding of the complexities involved. By following a rigorous plan and conforming to the regulations outlined by authorities such as the FDA and EMA, pharma professionals can mitigate risks associated with these critical assays. Comprehensive knowledge of viral clearance validation, effective spiking study implementation, and adherence to stringent COI protocols ensures that biologic products maintain their integrity and efficacy from development to delivery. The establishment of robust PPQ and CPV frameworks serves to strengthen the overall quality assurance practices, leading to enhanced patient safety and treatment outcomes.